Last updated: March 19, 2026
What are the core issues in the case?
Indivior Inc. filed patent infringement claims against Actavis Laboratories UT, Inc. in the District of Delaware. The dispute centers on Actavis’s manufacture and sale of generic formulations purportedly infringing Indivior’s patents relating to Suboxone (buprenorphine/naloxone) products used to treat opioid dependence. The core patent claims involve a specific formulation and methods of production.
When did the case occur?
The complaint was filed in 2018. The case involves proceedings through at least 2022, with dispositive motions and settlement discussions occurring during this period.
What patents are involved?
Indivior asserted U.S. Patent Nos. 9,824,245 and 10,005,505, both covering formulations and methods related to Suboxone. The patents aim to prevent generic substitution until the patents’ expiration, which is late 2020s.
- U.S. Patent No. 9,824,245: Claims focus on a specific buprenorphine/naloxone formulation with particular ratios and excipients.
- U.S. Patent No. 10,005,505: Claims cover methods of manufacturing the formulation with an emphasis on stability and bioavailability.
What procedural milestones occurred?
- Complaint filed in 2018.
- Actavis launched generic Suboxone in 2019 following a Patent Office inter partes review (IPR) that challenged patent validity.
- Indivior filed motion for preliminary injunction, which was denied in 2019.
- The parties engaged in patent litigation, with motions to dismiss and summary judgment filed between 2020 and 2022.
- In 2021, the court issued an opinion invalidating some patent claims based on obviousness and anticipation.
- By 2022, the parties negotiated a settlement, with Indivior dismissing the case.
What was the outcome?
- Partial invalidation of patents in 2021.
- Settlement agreement in 2022, leading to potential licensing or cross-licensing terms.
- The case reflects the balance between patent rights and challenges introduced by inter partes review.
What legal issues and doctrines are involved?
- Patent validity: Claims challenged under obviousness and anticipation.
- Infringement: Whether Actavis’s generics contain formulations that infringe Indivior’s patented claims.
- Inter partes review: US Patent Office procedures used to contest patent validity.
- Preliminary injunctive relief: Court’s discretion to prohibit generic entry pending resolution.
How does this case compare to industry norms?
Similar litigations involve pharmaceutical patents with late-stage patent expiry. Post-AIA reforms have increased invalidations via IPRs. The settlement underscores the trend where litigants shift toward licensing agreements after patent validity is contested.
What are the implications for market and R&D?
- Patent challenges via IPRs are increasingly used to weaken patent portfolios.
- Success in invalidating patents can accelerate generic market entry, impacting revenue streams.
- Settlement indicates strategic balancing of litigation costs and market share considerations.
Key Takeaways
- Indivior’s patents faced validity challenges through IPR, resulting in partial invalidation.
- Settlement followed patent invalidation, indicating a possible licensing strategy.
- The case exemplifies legal and procedural tools available to both patent holders and challengers.
- Outcomes influence future patent strategies, especially in highly regulated pharmaceutical markets.
- The trend suggests increased reliance on administrative proceedings like IPR to defend or challenge patent rights.
FAQs
1. What are the main legal challenges posed to Indivior’s patents?
The patents faced invalidity arguments based on obviousness and anticipation, using prior art references that suggested the formulations were not novel or non-obvious.
2. How does inter partes review impact pharmaceutical patent litigation?
IPR proceedings allow the Patent Office to reevaluate patent validity post-grant, often resulting in claim cancellations or narrowing, which can influence litigation outcomes.
3. Did the case affect the launch timeline for generic Suboxone?
Yes. Even with patent invalidation, market entry often depends on settlement or court decisions, which delayed or altered generic timing.
4. What precedent does this case set for future patent litigations?
It underscores the power of IPRs to challenge patent validity and encourages settlement negotiations once invalidity is established.
5. Are there broader industry implications from this case?
Yes. It illustrates the increasing role of administrative proceedings in patent disputes and highlights the importance of patent strength in pharmaceutical markets.
Sources
- United States Patent and Trademark Office. (2021). Patent Trial and Appeal Board decisions.
- U.S. District Court for the District of Delaware. (2018-2022). Case filings and rulings.
- Indivior Inc. v. Actavis Laboratories UT, Inc., No. 1:18-cv-00497-RGA. (District of Delaware).
- Congressional Research Service. (2020). Patent validity challenges and pharmaceutical markets.
- Williams, J. (2022). The role of IPRs in pharmaceutical patent litigation. Bloomberg Law.
